OncoMatch/Clinical Trials/NCT07263906
Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia
Is NCT07263906 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Anti-LILRA6 CAR-T cells for refractory acute myeloid leukemia.
Treatment: Anti-LILRA6 CAR-T cells — This study aims to evaluate the safety and efficacy of LILRA6-directed chimeric antigen receptor T cells (LILRA6 CAR-T cells) in patients with refractory or relapsed acute myeloid leukemia(AML).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: LILRA6 overexpression (positive rate in bone marrow/tumor cells ≥ 20%)
The positive rate of LILRA6 expression in bone marrow/tumor cells is ≥ 20%
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: targeted LILRA6 drug
Those who have received any other targeted LILRA6 drug treatment before.
Lab requirements
Blood counts
Absolute number of neutrophils ≥ 0.5×10^9 /L, Platelet count ≥ 30×10^9 /L, Hemoglobin ≥ 7.0 g/dl
Kidney function
Creatinine clearance rate (Cockcroft-Gault method) ≥ 45 mL/min
Liver function
Alanine aminotransferase and Aspartate aminotransferase ≤ 2.5× UNL; Serum total bilirubin ≤ 1.5× UNL
Cardiac function
Ejection fraction of the heart (EF) ≥ 45%; NYHA class III or IV excluded
Sufficient organ function reserve: Alanine aminotransferase and Aspartate aminotransferase ≤ 2.5× UNL (upper limit of normal value); Creatinine clearance rate (Cockcroft-Gault method) ≥ 45 mL/min; Serum total bilirubin ≤ 1.5× UNL; Ejection fraction of the heart (EF) ≥ 45%; In an indoor natural air environment, baseline oxygen saturation > 92%; Blood routine: All of the following criteria are met: Absolute number of neutrophils ≥ 0.5×10^9 /L, Platelet count ≥ 30×10^9 /L, Hemoglobin ≥ 7.0 g/dl.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07263906 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior targeted LILRA6 drug disqualifies patients from enrollment.
Does this trial require LILRA6?
Yes, LILRA6 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages